Opinion: It’s time to get serious about the economics of expanded access
"Right to try" doesn't mean right to try for free. So who should pay for expanded access to experimental medicines, and how much should they pay?
As the winds of change blow away the lingering odors of the “right to try” miasma, it’s time to get serious about expanded access 2.0.
Last week, more than 500 people from industry, academia, government, and patient advocacy groups at the National Press Club in Washington to discuss, debate, and develop what comes next for expanded access, also known as compassionate use. The first voice to be heard was Dr. Janet Woodcock, director of the Food and Drug Administration’s Center for Drug Evaluation and Research, in a “fireside chat” I had the honor to moderate. Woodcock shared
